Keng-Liang Ou1, Chao-Chia Weng, Chi-Chang Wu, Yun-Ho Lin, Hsi-Jen Chiang, Tzu-Sen Yang, James Wang, Yun Yen, Han-Yi Cheng, Erwan Sugiatno. 1. *Professor, School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan; Professor, Department of Dentistry, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan; Director, Research Center for Biomedical Devices and Prototyping Production, Taipei Medical University, Taipei, Taiwan; Director, Research Center for Biomedical Implants and Microsurgery Devices, Taipei Medical University, Taipei, Taiwan. †PhD Student, School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan. ‡Graduate Institute of Nanomedicine, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan. §Professor, Department of Pathology, Taipei Medical University, Taipei, Taiwan. ¶Assistant Professor, Department of Dentistry, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan; Researcher, Research Center for Biomedical Devices and Prototyping Production, Taipei Medical University, Taipei, Taiwan. ‖Researcher, Research Center for Biomedical Devices and Prototyping Production, Taipei Medical University, Taipei, Taiwan; Associate Professor, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taipei, Taiwan. #Researcher, StemBios Technologies, Monterey Park, CA. **Professor, Department of Molecular Pharmacology, Beckman Research Institute of the City of Hope, Duarte, CA; Professor, Institute of Translational Medicine, Taipei Medical University, Taipei, Taiwan. ††Assistant Professor, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, Taipei, Taiwan; Researcher, Research Center for Biomedical Devices and Prototyping Production, Taipei Medical University, Taipei, Taiwan; Researcher, Research Center for Biomedical Implants and Microsurgery Devices, Taipei Medical University, Taipei, Taiwan. ‡‡Professor, Department of Prosthodontic, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta, Indonesia
Abstract
PURPOSE: The aim of the present study was to examine the osseointegration in low-density bone tissue for SLAffinity-treated implants with StemBios (SB) cell therapy. MATERIALS AND METHODS: The morphologies of SLAffinity-treated surfaces were characterized using scanning electron microscopy. In the animal model, implants were installed in the mandibular canine-premolar area of 12 miniature pigs. Each pig received 3 implants of machine, sand blasted, large grit, and acid etched, and SLAffinity-treated implants. In the clinical trial, 10 patients received 1 SLAffinity-treated implant in the maxilla in the posterior area and 1 patient with low bone tissue density received 2 SLAffinity-treated implants with SB cell therapy. Resonance frequency analysis and computed tomography were assessed monthly over the first 3 months after implant placement. RESULTS: The results demonstrated that surface treatment significantly affected early osseointegration in patients who received SB cell therapy. SB cell therapy transferred the stress caused by the implant more uniformly, and the stress decreased with healing time. SLAffinity-treated implants also proved clinically successful after the 3 months. CONCLUSION: The SLAffinity treatments enhanced osseointegration significantly, especially at early stages of bone tissue healing with SB cell therapy.
PURPOSE: The aim of the present study was to examine the osseointegration in low-density bone tissue for SLAffinity-treated implants with StemBios (SB) cell therapy. MATERIALS AND METHODS: The morphologies of SLAffinity-treated surfaces were characterized using scanning electron microscopy. In the animal model, implants were installed in the mandibular canine-premolar area of 12 miniature pigs. Each pig received 3 implants of machine, sand blasted, large grit, and acid etched, and SLAffinity-treated implants. In the clinical trial, 10 patients received 1 SLAffinity-treated implant in the maxilla in the posterior area and 1 patient with low bone tissue density received 2 SLAffinity-treated implants with SB cell therapy. Resonance frequency analysis and computed tomography were assessed monthly over the first 3 months after implant placement. RESULTS: The results demonstrated that surface treatment significantly affected early osseointegration in patients who received SB cell therapy. SB cell therapy transferred the stress caused by the implant more uniformly, and the stress decreased with healing time. SLAffinity-treated implants also proved clinically successful after the 3 months. CONCLUSION: The SLAffinity treatments enhanced osseointegration significantly, especially at early stages of bone tissue healing with SB cell therapy.